Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech’s next potential product addresses the extremely common problem of pain -- and could become its next ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication ...

RESTON, Va., Nov. 12, 2025 /PRNewswire/ -- V2X, Inc. (VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.25 million shares of its common stock on an ...

MCLEAN, Va., Aug. 8, 2025 /PRNewswire/ -- V2X, Inc. (VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.0 million shares of its common stock on an underwritten ...

RESTON, Va., Nov. 12, 2025 /PRNewswire/ -- V2X, Inc. (NYSE:VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.25 million shares of its common stock on an ...

Vertex will host a conference call at 8:30 a.m. Eastern Time today, November 3, 2025, to discuss its third quarter 2025 financial results. Those wishing to participate may do so by dialing ...